3 Top Gujarat-based Stocks to Watch for Future Multibagger Potential: Torrent Pharma, Zydus Lifesciences and Astral

Gujarat-based stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Torrent Pharma, Zydus Lifesciences and Astral meet that test, with market caps from Rs 38,753 crore to Rs 1.75 lakh crore and Torrent Pharma offering the highest return on equity at 25.49%. Gujarat's business culture has produced strong pharma and building-products companies headquartered in Ahmedabad.

This list covers listed companies headquartered in Ahmedabad, Gujarat, with complete, verifiable financials, ranked by market capitalisation. Not every name here is a largecap, so the list takes the leading companies of the sector by market capitalisation. Investors screening Gujarat-based stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Gujarat-based Stocks and Why Do They Attract Multibagger Interest?

Gujarat-based stocks are shares of companies headquartered in Ahmedabad, in a state known for business and industry. These companies sell medicines and plumbing products across India and in export markets.

Strong brands, well run plants and steady demand have helped Gujarat-based firms grow. Companies with healthy margins and good returns on equity are the ones investors compare in Gujarat-based stocks.

Gujarat-based Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 16 October 2026. Zydus Lifesciences has the lowest PE of the group at 24.78, while Torrent Pharma posts the highest return on equity at 25.49%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Torrent Pharmaceuticals	4,558.90	1,75,196	81.26	36.42	25.49%	1.79	3,480.60 to 5,250.00
Zydus Lifesciences	1,123	1,13,790	24.78	36.42	18.59%	0.46	835.50 to 1,232.10
Astral	1,427.40	38,753	67.31	36.61	13.18%	0.06	1,311.60 to 1,768.70

Torrent Pharma: 28.79% Profit CAGR Since FY22

Torrent Pharmaceuticals makes branded medicines for chronic therapies such as cardiac, gastro-intestinal and central nervous system care in India and overseas. It reported FY26 revenue of Rs 13,886.15 crore, up 20.34% year on year, and net profit of Rs 2,138.18 crore, up 11.87%. Net profit has compounded at 28.79% a year since FY22, while revenue has grown 12.38% a year. Operating margin was 22.70% in FY26.

In the June 2026 quarter, revenue rose 56.29% to Rs 4,909 crore and net profit grew 3.28% to Rs 566 crore. The share price has gained 194.63% over five years and 29.72% over the past year. Domestic institutions raised their holding from 9.28% in September 2025 to 12.87% in July 2026. The stock trades at a PE of 81.26 against an industry PE of 36.42, with a return on equity of 25.49%.

Zydus Lifesciences: 21.24% Profit CAGR Since FY22

Zydus Lifesciences develops and sells generic medicines, vaccines, consumer wellness products and specialty therapies. It reported FY26 revenue of Rs 27,657.90 crore, up 17.64% year on year, and net profit of Rs 5,026.40 crore, up 8.92%. Net profit has compounded at 21.24% a year since FY22, while revenue has grown 15.89% a year. Operating margin was 16.55% in FY26. The debt-to-equity ratio is 0.46.

The stock trades at a PE of 24.78 against an industry PE of 36.42, below the sector average, with a return on equity of 18.59%. Revenue for the June 2026 quarter rose 20.72% to Rs 8,123.10 crore, at an operating margin of 25.86%. The share price has gained 113.38% over five years and 15.79% over the past year. Domestic institutions raised their holding from 10.86% in September 2025 to 11.28% in September 2026.

Astral: Debt-to-Equity of 0.06

Astral makes CPVC and PVC pipes, fittings, adhesives and water tanks for plumbing and drainage in homes and buildings. It reported FY26 revenue of Rs 6,615.90 crore, up 12.64% year on year, and net profit of Rs 534.70 crore, up 3.04%. Revenue has compounded at 10.55% a year since FY22. Operating margin was 16.54% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.

In the June 2026 quarter, revenue rose 16.09% to Rs 1,590.80 crore and net profit grew 51.77% to Rs 120.20 crore. Domestic institutions raised their holding from 14.90% in June 2025 to 21.31% in June 2026. The stock trades at a PE of 67.31 against an industry PE of 36.61, with a return on equity of 13.18%.

Gujarat-based Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these Gujarat-based stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
Torrent Pharma	13,886.15	2,138.18	20.34%	12.38%	28.79%	33.73%
Zydus Lifesciences	27,657.90	5,026.40	17.64%	15.89%	21.24%	25.86%
Astral	6,615.90	534.70	12.64%	10.55%	2.19%	15.46%

Check the Univest Screener for live data on these Gujarat-based stocks

Institutional Holding in Torrent Pharma, Zydus Lifesciences and Astral

Institutional holding shows who is backing these Gujarat-based stocks alongside the promoter. The table uses the latest reported quarter for each. Astral has the deepest institutional backing, with FII and DII together holding 35.20% as of June 2026. Domestic institutions increased their holding over the past year in Torrent Pharma (from 9.28% to 12.87%), Zydus Lifesciences (from 10.86% to 11.28%) and Astral (from 14.90% to 21.31%).

Stock	Promoter	FII	DII	Public	Quarter
Torrent Pharma	60.78%	17.97%	12.87%	8.38%	July 2026
Zydus Lifesciences	75.01%	7.04%	11.28%	6.66%	September 2026
Astral	54.22%	13.89%	21.31%	10.58%	June 2026

Risks to Weigh in Gujarat-based Stocks

Being careful with Gujarat-based stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Pharma earnings depend on prescriptions and export pricing.
• Building product demand follows housing activity.
• Valuation: Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings need to keep growing to support the price.
• Concentration: Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Gujarat-based Stocks

Picking from Gujarat-based stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (36.42 to 36.61) and ask whether the growth rate justifies any gap.
3. Track revenue growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Torrent Pharma, Zydus Lifesciences and Astral live prices.

Conclusion

Among Gujarat-based stocks, Torrent Pharma stands out for the highest return on equity at 25.49%, Zydus Lifesciences for the lowest PE of the group at 24.78 and Astral for the strongest latest-quarter profit growth at 51.77%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing Gujarat-based stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Gujarat-based Stocks to Watch

Which are the best Gujarat-based stocks to watch for multibagger potential?

Ans. Torrent Pharma, Zydus Lifesciences and Astral are the 3 names this list highlights, with market caps of Rs 1,75,196 crore, Rs 1,13,790 crore and Rs 38,753 crore respectively. Torrent Pharma is notable for the highest return on equity at 25.49%. Zydus Lifesciences stands out for the lowest PE of the group at 24.78. Astral offers the strongest latest-quarter profit growth at 51.77%. These are watchlist names for Gujarat-based stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Torrent Pharma a good stock for long-term investors?

Ans. Torrent Pharma has a return on equity of 25.49%, a PE of 81.26 against an industry PE of 36.42 and a market cap of Rs 1,75,196 crore. Net profit has compounded at 28.79% a year since FY22, and FY26 revenue rose 20.34% while June 2026 quarter net profit grew 3.28%. Long-term returns in Gujarat-based stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Zydus Lifesciences become a multibagger from here?

Ans. Zydus Lifesciences has already gained 113.38% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Gujarat-based stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 21.24% a year since FY22, and FY26 revenue rose 17.64%. At a PE of 24.78 against an industry PE of 36.42, valuation should be checked against that growth before investing.

What is the market cap of Torrent Pharma, Zydus Lifesciences and Astral?

Ans. As of 16 October 2026, Torrent Pharma has a market cap of Rs 1,75,196 crore, Zydus Lifesciences has a market cap of Rs 1,13,790 crore and Astral has a market cap of Rs 38,753 crore. Torrent Pharma is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Gujarat-based stocks.

What are the risks of investing in Gujarat-based stocks?

Ans. The main risks are drug pricing in export markets, raw material costs and a slowdown in housing. Companies with strong brands and varied products handle these better. Torrent Pharma trades at a PE of 81.26 against an industry PE of 36.42, so earnings growth needs to hold up.

Why is Torrent Pharma trading at a PE of 81.26?

Ans. Torrent Pharma's PE of 81.26 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 25.49%, profit growth of 28.79% a year since FY22 and FY26 revenue growth of 20.34%, which also means the stock is more sensitive if growth slows. Investors in Gujarat-based stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.

How much do institutions hold in Torrent Pharma, Zydus Lifesciences and Astral?

Ans. As of the latest reported quarter, FII and DII together hold 30.84% of Torrent Pharma (17.97% and 12.87%), 18.32% of Zydus Lifesciences (7.04% and 11.28%) and 35.20% of Astral (13.89% and 21.31%). Rising institutional holding is a useful signal in Gujarat-based stocks, though it should be read with earnings trends rather than on its own.